Patients receiving live/attenuated vaccinations within 4 weeks prior to registration are not eligible
Use of any live vaccines within 4 weeks of initiation of study treatment
Use of any live vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.
Use of live vaccines within four weeks of starting abatacept
Live vaccines within 30 days prior to the first dose of trial therapy and during trial treatment.
Vaccination with live attenuated vaccines within 4 weeks of first study agent administration
Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.
Administration of live vaccines within 21 days prior to enrollment
Received live attenuated vaccines within 30 days of first dose.
Any vaccinations four weeks prior to the first vaccination cycle or live vaccines at any time during the study
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Vaccine administration of live vaccines within 28 days of enrollment
Live attenuated vaccinations 14 days prior to treatment
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Current or recent treatment with therapeutic antibiotics, live attenuated vaccines or systemic immunostimulatory/immunosuppresive medication
Non-oncology vaccines within 28 days prior to or after any dose of ipilimumab
Vaccination with live attenuated vaccines within 4 weeks of first study agent administration
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment
Any live, attenuated vaccine within 28 days prior to the first day of treatment or during study treatment, or unwillingness to avoid live, attenuated vaccines within 90 days following the last dose of atezolizumab
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
Use of non-oncology vaccines containing live virus for prevention of infectious diseases within 12 weeks prior to study drug
Live vaccines within 28 days prior to study pre-registration
Patients should not receive immunization with attenuated live vaccines within one week (7 days) of study entry or during study period
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Live vaccines are not permitted within 28 days of study registration
Live attenuated vaccinations within 14 days prior to treatment
Live attenuated vaccinations 14 days prior to treatment
Patients receiving live vaccines due to the expected bone marrow toxicity (applicable to combination part only).
Use of live vaccines against infectious disease (e.g. varicella) within 28 days of initiation of study therapy; killed vaccinations (e.g. influenza) are allowed at any appropriate time before and during the study
Newly diagnosed MCL: Major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug
Treatment with a live virus vaccine during the 3 months prior to baseline visit; no live vaccines will be allowed throughout the course of this study
Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment. Non-live vaccination (eg, influenza) are permitted anytime during treatment
Patients should not receive immunization with attenuated live vaccines =< 7 days of study entry or during study period
No immunizations with attenuated live vaccines within one week of study entry or during study period
Live-virus vaccines =< 28 days prior to registration
Previous treatment with radiotherapy, or immunotherapeutic agents, or receipt of live vaccines in the 4 weeks prior to study drug administration;
Use of any live vaccines within 4 weeks of initiation of study treatment.
Administration of live attenuated vaccines within 4 weeks of study enrollment.
Vaccination with live attenuated vaccines within 4 weeks of first study agent administration
TREATMENT: Patients who have received live attenuated vaccines within 1 week of the start are ineligible to receive everolimus
Patients who have received a live, attenuated vaccines within 4 weeks of first dose of drug
Patients should not receive immunization with attenuated live vaccines during study period or within 1 week of study entry
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
Vaccination with live, attenuated vaccines within 4 weeks of first dose of study drug
received live vaccines.
Administration of live attenuated vaccines within eight weeks of start of study treatment (day -1) and throughout the study
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Patients taking live vaccines including yellow fever vaccinations
Administration of live vaccines =< 14 days prior to registration; note: patients may not receive any viral immunizations during the study and for 28 days after the last dose of Reolysin
Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study
Use of live or live attenuated vaccines within 30 days prior to randomization
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Patients who received live vaccines or who have close contact with people who have received live vaccines within 7 days of day 1 of study treatment
Unwilling to avoid vaccinations with live vaccine and concomitant use of attenuated live vaccines
Receipt of live vaccines against infectious diseases within 28 days;
Live or attenuated vaccines (other than experimental cancer vaccine therapy) within 28 days prior to receiving the first dose of MEDI-551
Receipt of live vaccines with 4 weeks (28 days) of study
Live attenuated vaccinations 14 days prior to treatment
Patients should not receive immunization with attenuated live vaccines during study period
Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4 weeks prior to randomization
Receive immunization with attenuated live vaccines within one week of randomization or during the study period.
Vaccination with live, attenuated vaccines within 4 weeks of first dose of this study
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
Patients who have received vaccination with live attenuated vaccines within 6 months prior to registration are not eligible
Live attenuated vaccines
Live attenuated vaccines
Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.
RECIPIENT: Live attenuated vaccines
Live in the community
Live attenuated vaccines within 90 days prior to leukapheresis.
Vaccination with live attenuated vaccines within 4 weeks of study agent administration
Subjects must not have received a live attenuated vaccine within 28 days before the first dose of investigational agent, and subjects, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose of investigational agent.
Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment
Recent receipt of live attenuated vaccines.
Received live vaccines within 30 days prior to enrollment
